Korro Bio, Inc. (KRRO)
Korro Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $13.32, down 1.26% on the session, giving a market capitalisation of $132.6M. On trailing twelve-month figures it carries a trailing P/E of -1.33, a net margin of -4477.1%. Its beta of 2.21 implies it has historically moved more than the broad market.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Korro Bio, Inc. is most often compared with the following Healthcare names: